21-497 Phase I
An Open-Label, Multi-Center, Phase I Study of Oral IAG933 in Adult Patients with Advanced Mesothelioma and Other Solid Tumors
An Open-Label, Multi-Center, Phase I Study of Oral IAG933 in Adult Patients with Advanced Mesothelioma and Other Solid Tumors
An open-label, phase I, dose escalation, expansion study of MGY825 in adult patients with advanced non-small cell lung cancer
CHIO3 Trial: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer
Elucidating Novel Immune and Genomic Markers for ALK (ENIGMA+)
Genomically-Guided Treatment Trial in Brain Metastases
NVL-330-01: A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients with Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients with Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)
Phase 1/1b, Multicenter, Open-Label, Study of RMC 9805 in Participants With Advanced KRASG12D-Mutant Solid Tumors
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants with Advanced Solid Tumors